An alarming problem in the therapy of infective endocarditis: The development of antibiotic resistance;Un problema allarmante nella terapia delle endocarditi infettive: Lo sviluppo di antibiotico-resistenza

Italian Heart Journal Supplement

Volumn 6, Issue 3, 2005, Pages 121-127

  Enia, Francesco ^a,b   Bella, Rosario ^a   Mineo, Riccardo ^a   Mizio, Gisella ^a   Reina, Giuseppe ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Endocarditis; Infective endocarditis

Indexed keywords

BETA LACTAMASE; METICILLIN; PENICILLIN G; PEPTIDOGLYCAN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATION; DISEASE COURSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; ENTEROCOCCUS; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; REVIEW; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS;

EID: 29244466832     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Cabell CH, Jollis JG, Peterson GE, et al. Changing pattern characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-4.
2. Durack DT, Lukes AJ, Bright MK, et al. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96: 200-9.
3. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996; 24: 380-8.
4. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-21.
5. Eliopoulus GM. Enterococcal endocarditis. In: Kaye D, ed. Infective endocarditis. New York, NY: Raven Press, 1992: 209-29.
6. Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993; 342: 76-9.
7. Fontana RM, Ligozzi A, Mazzariol G, et al. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. Clin Infect Dis 1999; 27 (Suppl I): 1584-1586.
8. Angeletti S, Lorino G, Gherardi G, Battistoni F, De Cesaris M, Dicuonzo G. Routine molecular identification of enterococci by gene-specific PCR and 16S ribosomal DNA sequencing. J Clin Microbiol 2001; 39: 794-7.
9. Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect Dis 1999; 32: 11-6.
10. Konstantinov IE, Zehr KJ. Aortic root replacement in patients with vancomycin-resistant Enterococcus faecium endocarditis and leukaemia. Chest 2001; 120: 1744-6.
11. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158: 1127-32.
12. Pugliese G, Weinstein RA. Issues and controversies in prevention and control of vancomycin-resistant enterococci. Chicago, IL: Aetna Communications, 1998: 19-22.
13. Mekonen ET, Noskin GA, Haceck DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1: 249-53.
14. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant antibiotics. Clin Infect Dis 1997; 25: 1260-70.
15. Losonsky GA, Wolf A, Schwalbe RS, et al. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994; 19: 163-5.
16. Leclerq R, Bingen E, Su QH, et al. Effects of combination of beta-lactams, daptomycin, gentamicin and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991; 35: 92-8.
17. Brandt CM, Rouse MN, Laue NW, et al. Effective treatment of multidrug resistant enterococcal experimental endocarditis with combinations of cell wall active agents. J Infect Dis 1996; 173: 909-13.
18. Rambaldi N, Ambrosone C, Migliaresi S, Rambaldi A. Combination of co-trimoxazolo and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. J Antimicrob Chemother 1997; 40: 737-8.
19. Sacker HL, Miller WC, Landau SW, et al. Relapsing native valve enterococcal endocarditis: a unique cure with oral ciprofloxacin combination therapy. J Clin Pharmacol 1991; 31: 719-21.
20. Tripodi MF, Locatelli A, Adinolfi LE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin resistant enterococcus. Eur J Clin Microbiol Infect Dis 1998; 155: 734-6.
21. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993; 37: 2069-73.
22. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster NG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20: 1137-44.
23. Lautenbach E, Shuster MG, Biker WB, Brennan PJ. The role of chloroamphenicol in the treatment of bloodstream infection due to vancomycin-resistant enterococcus. Clin Infect Dis 1998; 27: 1259-65.
24. Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994; 20: 41-3.
25. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994; 344: 1025-6.
26. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39 (Suppl A): 145-51.
27. Moellering LC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin-dalfopristin for the treatment of infection caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251-61.
28. Aeschlimann JR, Zervos MJ, Rjbak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59 500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocarditis vegetations. Antimicrob Agents Chemother 1998; 42: 2710-7.
29. Eliopoulos GM, Wennestern CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996; 40: 1745-7.
30. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999; 28: 689-90.
31. Waldvogel FA. Staphylococcus aureus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Benett's principles and practice of infectious diseases. 4th edition. New York, NY: Churchill Livingstone, 1995: 1754-77.
32. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
33. Watanakunakorn C, Tan JS, Phair JP. Some salient features of Staphylococcus aureus endocarditis. Am J Med 1973; 54: 473-81.
34. Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW, Burkley MJ. Risk factors for the development of prosthetic valve endocarditis. Circulation 1985; 72: 31-7.
35. John MD, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26: 1302-9.
36. Takayama Y, Yoshida K, Yamaguchi Y, et al. Investigation of infective endocarditis clinical isolates of methicillin resistant Staphylococcus aureus non-responsive to vancomicin. Kansenshogaku Zasshi 2001; 75: 473-9.
37. Miller MA, Dascal A, Portnoy J, et al. Development of mupiricin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupiricin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-3.
38. Atkinson BA, Lorian V. Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J Clin Microbiol 1984; 20: 791-6.
39. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY Study. J Clin Microbiol 2001; 39: 3727-32.
40. Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Regnier B. Prevalence and risk factors for carriage of methicillin resistant Staphylococcus aureus at admission to the intensive care unit. Arch Intern Med 2003; 163: 181-8.
41. Verhoef J. Stopping short the spread of methicillin-resistant Staphylococcus aureus. CMAJ 2001; 165: 31-2.
42. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316: 927-31.
43. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
44. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th edition. Approved standard, M7-A5. Wayne, Pennsylvania, PA: National Committee for Clinical Laboratory Standards, 2000.
45. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
46. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493-501.
47. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12 201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-8.
48. Hiramatsu K, Haritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
49. Aldeen DA. A non multiresistant community MRSA exposes its genome. Lancet 2002; 359: 1791-2.
50. Udo EE, Pearman GW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25: 97-108.
51. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 1999; 286: 1201-5.
52. Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001; 20: 860-3.
53. Hussain FM, Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus colonization in healthy children attending an outpatient clinic. Pediatr Infect Dis J 2001; 20: 763-7.
54. Lessing MP, Raftery MJ. Vancomycin-resistant Staphylococcus aureus. Lancet 1999; 351: 601-2.
55. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15.
56. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly 2002; 51: 565-7.
57. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly 2001; 50 (RR-5): 1-43.
58. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of Staphylococcal infections associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly 1997; 46: 626-35.
59. Center for Disease Control and Prevention. Monitoring hospital-acquired infections to promote patient safety - United States, 1990-1999. MMWR Morb Mortal Wkly 2000; 49: 149-53.
60. CDC's Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-13.
61. Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 1997; 350: 1644-5.
62. Boucher HW, Thauvin-Eliopoulos C, Loenberderg D, Eliopoulos GM. In vivo activity of evernimicin (SCH 27 899) against methicillin-resistant Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 2001; 45: 208-11.
63. Report of combined Working Party of the British Society for Antimicrobial Chemotherapy, The Hospital Infection Society and the Infection Control Nurses association. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infections in hospitals. J Hosp Infect 1998; 39: 253-90.
64. Chaix C, Durand-Zaleski I, Alberti C, Bran-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus. A cost-benefit analysis in an intensive care unity. JAMA 1999; 282: 1745-51.
65. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001; 22: 99-104.
66. Teare EL, Barrett SP. Stop the ritual of tracing colonised people. BMJ 1997; 314: 665-6.
67. Farrington M, Redpath C, Trundle C, Coomber S, Brown NM. Winning the battle but losing the war: methicillin-resistant Staphylococcus aureus (MRSA) infection at a teaching hospital. QJM 1998; 91: 539-48.
68. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357: 1225-40.